Targeted alpha therapy (TAT) is an emerging option for local and systemic cancer treatment. Preclinical research and clinical trials show that alpha-emitting radionuclides can kill targeted cancer cells while sparing normal cells, thus reducing toxicity. (223)RaCl2 (Xofigo(®)) is the first alpha emitting radioisotope to gain registration in the US for palliative therapy of prostate cancer bone ...

the tp53 gene is one of the most frequently mutated genes amongst human malignancies, particularly tp53 codon 72 polymorphism. furthermore, an association between the tp53 codon 72 variants and prostate cancer has been reported in several studies. although some studies have indicated an association between the tp53 arg/arg variant and an increased risk for prostate cancer, other studies have sh...